An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy

Area of Science:

• Urology
• Medical Technology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms in elderly men.
• Transurethral resection of the prostate (TURP) is the conventional treatment for BPH.
• Minimally invasive therapies (MITs) are emerging as alternatives to TURP, offering improved safety and fewer side effects.

Purpose of the Study:

• To provide an update on recent and heavily studied MITs for BPH.
• To analyze the mechanism of action, tolerability, and clinical efficacy of these MITs.
• To compare the readiness and potential of various emerging BPH treatment modalities.

Main Methods:

• Review of current literature on minimally invasive therapies for BPH.
• Analysis of clinical data for prominent MITs like UroLift and Rezuum.
• Evaluation of newer mechanical therapies, including nitinol devices, ClearRing, ZenFlow Spring, and Butterfly.

Main Results:

• UroLift and Rezuum are leading MITs due to robust clinical data.
• Newer mechanical therapies avoid tissue cutting, ablation, or heating.
• Significant variation exists in the clinical readiness of different MITs.

Conclusions:

• MITs are challenging traditional BPH treatments like TURP.
• UroLift and Rezuum are currently at the forefront of minimally invasive BPH treatment.
• Long-term studies are needed to determine the ultimate acceptance of emerging BPH therapies by patients and urologists.